Clinical Trial

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a randomized (1:1) phase III open label study of frontline mini-MTX plus methylprednisolone 2mg/kg/day compared to methylprednisolone 2mg/kg in allogeneic stem cell transplant recipients with grade 2-4 aGVHD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-19; most recent amendment 2025-05-28.
Status change: Not Yet Recruiting → Recruiting 2023-10-07
Trial Details
NCT Number NCT05921305
Lead Sponsor Peking University People's Hospital
Conditions Acute Graft Versus Host Disease
Enrollment 218 participants
Start Date 2023-08-03
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-03